| No. | Cell Type | Patent No. | Disease | Summary | Route of Administration | Refs. |
|---|---|---|---|---|---|---|
| 1 | iPSCs | CN103627669 | Retinal neuronal disorders e.g. AMD, RP | Method of inducing human pluripotent cells to obtain retinal precursor cells like pigment epithelial precursor cells and neurofilament progenitor cells. The invention induces the cells with Neurobasal medium, knockout serum replacement and nicotinamide so as to overcome low differentiation efficiency and reduce the cell differentiation time period. | - | [22] |
| 2 | iPSCs | US2015/0368713A1 | Retinal degenerative disorders like AMD, RP, Stargardt’s disease, Glaucoma and diabetic retinopathy | Method to utilize iPSCs (somatic cells) to obtain retinal pigment epithelium cells for their use in screening assays, therapeutics with their pharmaceutical compositions described in the invention and to study RPE. The iPSCs are produced from somatic cells such as fetal retinal pigment epithelial stem cells. | Polymeric scaffold/extracellular matrix and cell suspensions | [23] |
| 3 | iPSCs | CN105274049 | Treatment and recuperation of optic nerve injury | The invention provides a procedure to induce directional differentiation of iPSCs-derived 3D retinas into retinal ganglion cells in vitro wherein a nerve cell layer is digested into a single cell which is used as seed junction to produce functional RGCs using various media compositions. | - | [24] |
| 4 | iPSC’s | US20140127803A1 | Bilateral Corneal diseases | This patent describes the procedure to transform induced pluripotent stem cells to corneal epithelium cells in presence of amniotic membrane. | - | [27] |
| 5 | iPSC’s | US20180010093A1 | Damaged or diseased ocular surface | This invention relates to a method for inducing the differentiation of corneal epithelial cells in serum-free media from human pluripotent stem cells. | - | [28] |
| 6 | iPSC’s | WO2018037161A1 | Corneal diseases | The patent describes methods to differentiate pluripotent cells into corneal cells. | - | [29] |